Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINE1 | P05121 | 2/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.37 |
| ▸ | CCR9 | P51686 | 6/20 | 0.35 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CENPE | Q02224 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806816 | 0.73 | SERPINE1 (0.60) | SERPINE1PPARGMAPTFOLH1TACR1 | |
| SCHEMBL4096172 | 0.70 | FEN1 (0.35) | CCR9PTGESFOLH1 | |
| SCHEMBL4093710 | 0.67 | TACR1 (0.40) | PTGESTACR1 | |
| SCHEMBL2809577 | 0.64 | PPARG (0.51) | SERPINE1PPARGFOLH1 | |
| SCHEMBL2806758 | 0.62 | SERPINE1 (0.63) | SERPINE1MDM2PPARGFOLH1 | |
| SCHEMBL4092414 | 0.61 | PTGES (0.72) | SERPINE1CCR9PTGESMAPT | |
| SCHEMBL15511862 | 0.61 | SERPINE1 (0.43) | SERPINE1MDM2PTGESPPARG | |
| SCHEMBL4086605 | 0.61 | TACR1 (0.40) | MAPTTACR1 | |
| SCHEMBL2807174 | 0.60 | SERPINE1 (0.61) | SERPINE1CCR9PPARGFOLH1 | |
| SCHEMBL4092069 | 0.57 | MAPT (0.42) | GRIA2GRIA4MDM2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069384-A1 | THIENOPYRROLES USEFUL IN THE TREATMENT OF INFLAMMATION | NPY5R, TH, PTGES | SERPINE1 1731/4885GRIA2 1642/4885GRIA4 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.